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Abstract
Background: Breast cancer incidence in India is on rise. We report epidemiological, clinical and survival patterns of
breast cancer patients from community perspective.
Methods: All breast cancer patients treated at this hospital from July 2000 to July 2005 were included. All had cytological
or histological confirmation of breast cancer. TNM guidelines for staging and Immunohistochemistry to assess the
receptor status were used. Either lumpectomy with axillary lymph node dissection or Modified radical mastectomy
(MRM) was done for operable breast cancer, followed by 6 cycles of adjuvant chemotherapy with FAC or CMF regimens
to patients with pT >1 cm or lymph node positive or estrogen receptor negative and radiotherapy to patients after breast
conservation surgery, pT size > 5 cm, 4 or more positive nodes and stage IIIB disease. Patients with positive Estrogen
receptor or Progesterone receptor were advised Tamoxifene 20 mg per day for 3 years. Descriptive analysis was
performed. Independent T test and Chi-square test were used. Overall survival time was computed by Kaplan – Meier
method.
Results: Of 1488 cancer patients, 122 (8.2%) had breast cancer. Of 122 patients, 96.7% had invasive breast carcinoma
and 3.3% had sarcoma. 94% came from the rural and semi urban areas. Premenopausal women were 27%. The median
age was 50 years. Stage I-6.8%, II-45.8%, III-22%, IV-6.8%, Bilateral breast cancer – 2.5%. The mean pT size was 3.9 cm.
ER and PR were positive in 31.6% and 28.1% respectively. MRM was done in 93.8%, while 6.3% patients underwent breast
conservation surgery. The mean of the lymph nodes dissected were 3. CMF and FAC regimens were used in 48.8% and
51.2% of patients respectively. FAC group were younger than the CMF group (43.6 yr vs. 54 yrs, P = 0.000). Toxicities
were more in FAC than CMF group, alopecia (100% vs. 26.2%), grade2 or more emesis (31.8% vs. 9.2%), grade2 or more
fatigue (40.9% vs.19%), anemia (43.1% vs. 16.6%). Median Survival for the cohort was 50.8 months. ER positive patients
had better median survival (P = 0.05).
Conclusion: MRM was the most frequent surgical option. CMF and FAC showed equivalent survival. FAC chemotherapy
was more toxic than CMF. ER positive tumors have superior survival. Overall 3 year survival was 70 percent
Published: 23 May 2007
World Journal of Surgical Oncology 2007, 5:56 doi:10.1186/1477-7819-5-56
Received: 2 October 2006
Accepted: 23 May 2007
This article is available from: http://www.wjso.com/content/5/1/56
© 2007 Kuraparthy et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.World Journal of Surgical Oncology 2007, 5:56 http://www.wjso.com/content/5/1/56
Page 2 of 7
(page number not for citation purposes)
Background
Breast cancer is the most common cancer in the women of
developed countries. Survival in breast cancer patients has
improved substantially over the years as a result of multi-
modal treatment, comprising of local treatment by sur-
gery and radiotherapy; systemic treatment by
chemotherapy and hormonal therapy. Present research is
focused on further refinement of each of these treatments
in an attempt to preserve the organ and reduce the imme-
diate and delayed toxicities. Studies on early stage breast
cancer (EBC) from the developed countries have reported
20 year survival rates [1].
In India, without a significant reduction in carcinoma cer-
vix, women are exposed to the increased risk of breast can-
cer, as demonstrated by the project "Development of An
Atlas of Cancer In India", this study showed that age-
adjusted incident rates of breast cancer was more than that
of cervical cancer in 11 population based cancer registries
(PBCR), with sole exception of a rural PBCR at Barshi
[2,3].
Health care inequalities exist in India. As a result of inap-
propriate concentration of comprehensive cancer centers
to metros, only a fraction of total breast cancer patients
could access these services. It is therefore, not unusual to
find suboptimal treatment of breast cancer in the rural
and semi urban regions of India. Various studies on breast
cancer published from India reflect the disease profile and
treatment characteristics unique to the urban rich and the
middle class patients. The breast cancer profile at commu-
nity level is largely unrepresented. Breast cancer is the sec-
ond most frequent at this hospital, situated and catering
to the rural patients [4]. We report the epidemiology, clin-
ical characteristics and treatment patterns from a rural per-
spective. 3 year survival is included.
Methods
All breast caner patients who were treated at this hospital
from July 2000 to July 2005 were included. All had cyto-
logical and/or histological confirmation of breast cancer.
Patients were staged as per TNM guidelines. Chest-X ray,
Ultrasound of liver was done for all, while Bone scan was
done for Stage IIIB patients. Hormone receptor status was
assessed by Immunohistochemistry, a quick score of 5
and above was considered positive. Cardiac status was
assessed by Electrocardiogram and Echocardiogram for
patients in anthracyline group.
Surgery
Surgery, either lumpectomy with axillary dissection or
Modified radical mastectomy was done upfront for oper-
able breast cancer. Some patients, who had surgery at
peripheral hospitals and private clinics, were also
included after slide review and provided that they had
completed adjuvant treatment and follow up at our hos-
pital. Premenopausal women who do not attain meno-
pause after chemotherapy were advised bilateral
oopherectomy.
Chemotherapy
All patients with pT >1 cm or axillary lymph node positive
or estrogen receptor negative were given adjuvant chemo-
therapy. Adjuvant chemotherapy protocols included FAC
(5 FU 600 mg/m2, Doxorubicin 60 mg/m2 and cyclo-
phosphamide 600 mg/m2 given as i.v. infusion once
every 21 days) or CMF regimens (Cyclophosphamide 600
mg/m2, Methotrexate 40 mg/m2 and 5 FU 600 mg/m2
given on day1 and day8 as i.v infusion repeated every 28
days). Maximum of 6 cycles of chemotherapy were given.
CMF regimen was given to elderly patients, with clinical
cachexia and economically underprivileged. Patients hav-
ing locally advanced cancer were given neoadjuvant
chemotherapy, which was followed by surgery. Patients
with positive Estrogen receptor and/or Progesterone
receptor were advised Tamoxifene 20 mg per day for 3
years, after completion of chemotherapy.
Radiotherapy
Radiotherapy was given to all those who underwent breast
conservation surgery. Additionally, patients having pT >5
cm, four or more positive axillary lymph nodes, close or
positive surgical margins and all stage IIIB patients were
given radiotherapy. Patients without data on pT size and
axillary nodes were advised adjuvant radiotherapy. Radio-
therapy was given after completion of chemotherapy. Pal-
liative radiotherapy for painful skeletal lesions was also
given in metastatic setting.
Statistics
Descriptive analysis was performed for baseline demo-
graphics, response rates and toxicities. Independent T test
was used to compare two chemotherapy groups. Chi-
square test was used to explore the association between
the categorical variables. Survival time was calculated
from the date of diagnosis to the last follow up known to
be alive or death. Kaplan – Meier method and log – rank
test was used to compute overall survival.
Results
Of 1488 cancer patients treated during this period, 122
(8.2%) had breast cancer. Of 122 breast cancer patients
118 (96.7%) patients had invasive breast carcinoma,
while 4 (3.3%) patients had sarcoma. Sarcoma patients
were not included for analysis. Clinical features are pro-
vided in Table 1. Only 14.4% of women had meaningful
education of degree and above. 55% of women came from
the rural background, while 39% of them were from semi
urban areas. Premenopausal women comprised 27% of
the cohort. Family history of any solid tumor was reportedWorld Journal of Surgical Oncology 2007, 5:56 http://www.wjso.com/content/5/1/56
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in 17% of patients (table 2). Mean age at first delivery was
21 years. Mean reproductive period (Age at Menopause
minus Age at Menarche) was 32 years. Mean weight of the
whole cohort was 56.8 kg, while the mean Body Mass
Index (BMI) was 24.1.
Early breast cancer and as well as metastatic breast cancer
was marginal at 6.8% each. Of 96 operated patients, only
14 (14.6%) had data on pT size. The mean pT size was 3.9
cm. Fifty-seven (48.3%) had information on receptor sta-
tus. ER was positive in 38.6% of patients and PR was pos-
itive in 33.3% patients. Only 15.8% of patients were both
ER and PR positive.
Of 96 patients who had surgery, 55 (57.3%) patients had
surgery at tertiary care hospital, while 42.7% patients had
surgery at peripheral hospitals and private clinics. Mastec-
tomy was done in 93.8% patients, while 6.3% patients
underwent breast conservation surgery (BCS). Seventy-
one (73.9%) had information on axillary lymph nodal
status, out of these 33 (46.5%) patients had information
on the number of nodes dissected. The mean of the lymph
nodes dissected were 3. Of 96 patients who underwent
surgery, 86 (89.6%) patients received chemotherapy. Of
86 patients who received chemotherapy, 11(12.8%) were
in neoadjuvant setting. CMF and FAC regimens were used
in 48.8% and 51.2% of patients respectively. The charac-
teristics of the two chemotherapy groups are listed in the
table 3. The mean of chemo cycles received was 4.9 and
5.3 in CMF and FAC groups respectively (P = 0.27). The
distribution of estrogen receptor positive patients were
not significant between two chemotherapy groups (chi-
square P = 0.5). Thirty-eight patients received hormonal
therapy. Mean duration of Tamoxifene treatment was 13.5
months.
Toxicity
Toxicities (Table 4) were assessed in patients who received
chemotherapy. FAC regime was particularly more toxic
across all the events reported. Mucositis was seen in 4.8%
and 13.6% of CMF and FAC group patients respectively (P
= 0.15). Alopecia was seen in all FAC patients and in
26.2% of CMF group (P = 0.000). Grade2 and more, eme-
sis was seen in 9.2% of CMF and 31.8% of FAC patients
(P = 0.05). Grade3 and above, nausea was seen in 2.4% of
CMF and 9.1% of FAC patients (P = 0.12). Grade2 and
more fatigue was seen in 19% of CMF and 40.9% of FAC
group patients (Chi-square P = 0.02). High risk neutro-
penic sepsis was seen in 2.4% of CMF patients and 6.8%
of FAC patients (P = 0.58). One patient (2.3%) died due
to neutropenic sepsis in FAC group and none in CMF
group. Significant anemia requiring transfusion was seen
in 43.1% patients of FAC group and 16.6% of CMF
patients (P = 0.007).
Table 1: Clinical features (Figures in parenthesis show percentage)
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Additionally 12 patients (10.2%) had lymph edema of the
upper limb on affected side.
Two patients had radiation pneumonitis, one recovered
and another died. Three patients had wound infection.
Response
Of 118 patients, 33 (28%) relapsed, 52 patients (44.1%)
were in remission, 9 (7.6%) had progressive disease.
Twenty-four patients (20.3%) had no follow-up.
Survival
Median Survival for the whole cohort was 50.8 months
(95% CI 30.7, 70.8). The 3 year survival was 70 percent
(Figure 1). ER positive patients did not reach the median
survival (Figure 2), whereas for ER negative patients it was
39.4 months (P value = 0.05). Median survival in post
menopausal women was 39.4 months and while it was
50.8 months in premenopausal women (P = 0.84).
Median survival for CMF chemotherapy group was 50.8
months and FAC group did not reach median survival (P
= 0.50).
Patterns of relapse
Of 33 patients, who had relapsed, 48.4% had skeletal
metastases, 27.2% had lung metastases, 12% had liver
metastases and 9% had brain metastases. Chest wall recur-
rence was seen in 33.3% patients and 21.2% patients had
lymph nodal relapse.
Discussion
In this study we found that MRM was the most common
primary surgical option for breast cancer. The adjuvant
chemotherapy protocols CMF and FAC regimes have
shown equivalent survival rates. CMF was less toxic. ER
positive patients had superior survival. The compliance of
i.v. chemotherapy was good; however the duration of hor-
monal therapy was suboptimal. Half of the patients did
not have data on receptor status and one third on axillary
lymph nodal status. Most tumors were receptor negative.
The 3 year overall survival was 70%.
Breast conservation surgery (BCS) followed by radiother-
apy was shown to be equivalent to MRM in survival [5,6].
Therefore, BCS has become the standard of care for early
breast cancer in developed countries [7], although some
regional differences in the use of this treatment have been
reported [8]. By contrast, MRM was the preferred primary
surgical treatment for operable breast cancer in India,
including in major urban centers. A study from Delhi
showed only 11.3% underwent BCS, while MRM was per-
formed in 88.7% patients [9]. Even in affluent non-west-
Table 3: comparison of chemotherapy groups
variable group N Mean Stan Dev t mean Difference Pvalue
Age CMF 42 54.0 9.42 4.99 10.4 0.000
FAC 44 43.6 9.97
Weight (kg) CMF 40 54.0 11.11 -2.42 -5.4 0.018
FAC 42 59.4 8.91
Body mass index CMF 40 23.1 4.36 -1.75 -1.6 0.083
FAC 42 24.6 3.75
Lymph nodes CMF 14 3.0 1.25 0.28 0.2 0.784
FAC 14 2.8 1.81
Tumor size (clinical) CMF 32 6.1 2.61 0.67 0.7 0.505
FAC 40 5.4 1.98
Hemoglobin CMF 30 11.6 1.93 0.03 0.0 0.977
FAC 35 11.6 1.68
Albumin CMF 18 4.0 0.31 1.09 0.1 0.283
FAC 22 3.8 0.50
Table 2: Frequencies of risk factors for breast cancer
Parameter Yes (%) No (%) Missing Data (%)
menopause 70 (59) 32(27) 16(14)
Abortion 29(25) 71(60) 18(15)
Oral contraceptive pill use 4(3) 112(95) 2(2)
Breast fed 78(66) 2(2) 38(32)
Family history of any cancer 20(17) 85(72) 13(11)
Education(Degree and above) 17(14) 69(59) 32(27)
Diabetes 25(21) 60(51) 33(28)
mixed diet 91(77) 12(10) 15(13)World Journal of Surgical Oncology 2007, 5:56 http://www.wjso.com/content/5/1/56
Page 5 of 7
(page number not for citation purposes)
ern countries this seems to be the case [10]. Access to
radiotherapy facility was shown to influence the use of
BCS [11]. In the present study, only 6.3% patients under-
went breast conservation surgery. Generally, the axillary
dissection for most patients was inadequate, as exempli-
fied by the fewer number of nodes examined. Further
more, the pathology reports were lacking on pT size and
histological grade. These two are very crucial information
for optimal treatment of breast cancer. The advanced stage
and lack of radiotherapy facility are possible reasons for
the infrequent use of BCS.
The EBCTG meta-analysis published in 1992 reported
that the adjuvant chemotherapy reduced the annual odds
of recurrence by 40% in patients younger than 50 years of
age with ER negative tumors and by 33% in those with ER
positive disease [12]. In patients above 50 years, adjuvant
chemotherapy had reduced the annual odds of recurrence
by 30% in ER negative tumors and by 18% in ER positive
tumors. Overall, poly chemotherapy significantly reduced
the annual odds of recurrence and death by 24% and 15%
respectively. Anthracyline based regimens resulted in a
survival benefit when compared to CMF-like regimens,
with improvement in annual odds of recurrence and
death of 11% and 12%, respectively. Toxicity profile is dif-
ferent for CMF and anthracycline based regimens. Various
toxicities were more with FAC than CMF in elderly [13].
FAC regimen is costlier than the CMF; the cost becomes
even more, if the cost of supportive treatment for toxicities
are taken in to consideration. For these reasons, we have
preferred CMF for poor, elderly patients. The compliance
with either chemo regimen was good. Expectedly the FAC
regimen was more toxic and the median survival between
the two groups was not statistically significant. To demon-
strate 10% difference between the two groups would
require a large sample size.
Estrogen receptor is a well established predictive and
prognostic factor in breast cancer. The recent international
consensus on treatment for early breast cancer [14], the
panel affirmed that the first consideration was endocrine
responsiveness and suggested categorization of breast can-
cer in to endocrine responsive, endocrine non responsive
and tumors of uncertain endocrine responsiveness. There-
fore, testing for estrogen and progesterone receptor status
is critical to plan optimal treatment for breast cancer.
Estrogen receptor positive rates were reported to be lower
in Indian patients than those in western countries. A study
ER status and survival Figure 2
ER status and survival.
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Mucositis(Grade3 and more) 8(9.3)
Nausea (Grade3 and more) 5(5.8)
High risk febrile neutropenia 3(3.5)
Overall survival Figure 1
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from Mumbai, found ER and PR positive rates of 32.6%
and 46.1% respectively [15]. Additionally, not all patients
in India undergo the hormone receptor testing, as shown
by a study from Delhi; only 35.5% patients had receptor
testing [9]. In India, there is a concern about rising inci-
dence of breast cancer in young women; premenopausal
women comprised 50% of the cohort in an urban study
[9]. However in the present study the premenopausal
women formed one-fourth of the cohort. This suggests
that the breast cancer in young Indian women may be an
urban phenomenon.
In our study, only 48.3% Patients had hormone receptor
testing. The mean duration of compliance with
tamoxifene was 1.3 years. Even in developed countries the
use of Tamoxifene was found to be suboptimal at commu-
nity level [16]. Nonetheless, the reasons for this poor
compliance in our patients require investigation and
improvement.
Survival rates in breast cancer patients have been reported
from some registries in India. Five-year overall survival
rate in the Bangalore population based registry was 42.3%
[17]. The Madras Metropolitan Tumor Registry reported
survival rates of 80%, 58% and 48% at 1 year, 3 year and
5 years respectively [18]. A study from Kerala showed five
year survival rate of 40% [19]. In the present study, the
overall survival rate at 3 years was 70%, demonstrating the
feasibility of achieving comparable results at community
level by improving the infrastructure.
Conclusion
To move forward in the breast cancer care, breast cancer
physicians in India face major challenges. Some of them
are lack of information on histological grade of the tumor,
pT size, axillary lymph node clearance and receptor status.
The skills required by surgeons and pathologists to
address these issues can be imparted by conducting work-
shops and Continuing Medical Education programs. On
chemotherapy front, Taxanes and the monoclonal anti-
bodies are unlikely to be used at community level in
India, in the foreseeable future. The sequential adjuvant
hormonal treatment, with falling prices of aromatase
inhibitors, is promising. Therefore, it is necessary for the
oncology community in a poor country like India to
develop minimum practice guidelines for breast cancer
management.
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